Verteporfin exhibits YAP-independent anti-proliferative and cytotoxic effects in endometrial cancer cells
Metrics: PDF 2201 views | HTML 2775 views | ?
Venkata Ramesh Dasari1, Virginia Mazack1, Wen Feng2, John Nash1, David J. Carey1, Radhika Gogoi1
1Weis Center for Research, Geisinger Medical Center, Danville, PA, USA
2Henry Hood Center for Health Research, Geisinger Medical Center, Danville, PA, USA
Radhika Gogoi, email: firstname.lastname@example.org
Keywords: endometrial carcinoma, hippo pathway, verteporfin, YAP, organoids
Received: October 07, 2016 Accepted: January 24, 2017 Published: February 22, 2017
Endometrial Carcinoma (EMCA) is the most common gynecologic malignancy and the fourth most common malignancy in women in the United States. Yes-associated protein (YAP) is a potent transcription coactivator acting via binding to the TEAD transcription factor, and plays a critical role in organ size regulation. Verteporfin (VP), a benzoporphyrin derivative, was identified as an inhibitor of YAP-TEAD interaction. We investigated the therapeutic efficacy and mechanism of VP in EMCA. The efficacy of VP on cell viability, cytotoxicity and invasion was assayed in EMCA cell lines. An organoid model system was also developed to test the effect of VP on apoptotic markers in an in vitro model system. Treatment with VP resulted in a decrease in cell viability, invasion and an increase in cytotoxicity of EMCA cells. These effects occurred as early as 15 minutes following treatment. Similarly, VP treatment versus vehicle control increased apoptosis in human organoid model systems. Quantitative RT-PCR, cDNA based RTPCR array analysis and western blotting were performed to investigate the mechanism of VP action. The cytotoxic and anti-proliferative effects appeared to be independent of its effect on YAP. Our results suggest that VP is a promising chemotherapeutic agent for the treatment of endometrial cancer.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.